HCPLive Network

Long-Acting Clotting Agent Approved for Form of Hemophilia

MONDAY, March 31, 2014 (HealthDay News) -- The drug Alprolix has been approved by the US Food and Drug Administration (FDA) as the first long-acting hemophilia B clotting agent, the FDA said in a news release.

The product, formally known as "coagulation factor IX recombinant Fc Fusion protein" is the first hemophilia B remedy designed to require less frequent injections than prior treatments, the FDA said. It was approved to help control and prevent bleeding episodes and to manage bleeding during surgery.

Alprolix was evaluated in clinical studies involving 123 people, ages 12-71, with severe hemophilia B. No safety issues were identified during the trials, the FDA said.

The product is manufactured by Biogen Idec, located in Cambridge, Mass.

More Information


Copyright © 2014 HealthDay. All rights reserved.


Further Reading
Clinicians who treat patients suffering with osteoarthritis pain have a new low-dose nonsteroidal anti-inflammatory drug (NSAID) option at their disposal. Zorvolex (diclofenac) was developed to meet prevailing FDA recommendations regarding NSAID dosing and treatment duration.
One-pill regiment includes abacavir, dolutegravir and lamivudine.
Eliquis is also now indicated for reducing the risk of recurrent DVT and PE following initial therapy.
More Reading
$related2$